Journal profile · Hematology
Haemophilia
ISSN 1351-8216 · eISSN 1365-2516 · Wiley-Blackwell Publishing Ltd · UNITED STATES · Quarterly · Founded 1995
Haemophilia: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 2.91; hybrid open access; APC about USD 4,760; median 135 days to acceptance (100 articles, last 24 months); community-reported acceptance: fairly easy; 226 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Haemophilia is published by Wiley-Blackwell Publishing Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hemophilia Treatment and Research, Platelet Disorders and Treatments and Blood Coagulation and Thrombosis Mechanisms, together about 61.2% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Haemophilia is an international journal dedicated to the exchange of information regarding the comprehensive care of haemophilia. The Journal contains review articles, original scientific papers and case reports related to haemophilia care, with frequent supplements. Subjects covered include: clotting factor deficiencies, both inherited and acquired: haemophilia A, B, von Willebrand's disease, deficiencies of factor V, VII, X and XI replacement therapy for clotting factor deficiencies component therapy in the developing world transfusion transmitted disease haemophilia care and paediatrics, orthopaedics, gynaecology and obstetrics nursing laboratory diagnosis carrier detection psycho-social concerns economic issues audit inherited platelet disorders
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Cedric Hermans BrusselsPublisher website
Editorial board by country: none in mainland China; most named United Kingdom 15, United States 13, Sweden 4, Italy 3, Canada 3 (58 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hemophilia Treatment and ResearchMedicine36.2%
- Platelet Disorders and TreatmentsMedicine13.6%
- Blood Coagulation and Thrombosis MechanismsMedicine11.4%
- Coagulation, Bradykinin, Polyphosphates, and AngioedemaMedicine9%
- Hemostasis and retained surgical itemsMedicine3.2%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine3.1%
- Blood transfusion and managementMedicine2.5%
- Chronic Myeloid Leukemia TreatmentsMedicine2.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbaseCASCurrent ContentsPublisher website
Other: EBSCO
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.91LetPub ·
- Impact factor (publisher)
- 3Publisher website ·
- Impact factor (publisher) 2025
- 3Publisher website ·
- CiteScore 2026-06
- 4.4LetPub ·
- CiteScore (publisher)
- 4.4Publisher website ·
- CiteScore (publisher) 2025
- 4.4Publisher website ·
- SJR 2026-06
- 0.96LetPub ·
- SNIP 2026-06
- 0.97LetPub ·
- h-index
- 84LetPub ·
- h-index
- 123OpenAlex ·
- i10-index
- 3,484OpenAlex ·
- 2-year mean citedness
- 2.21OpenAlex ·
- Self-citation rate
- 23.3%LetPub ·
- Share of gold OA articles
- 54.23%LetPub ·
Volume
- Articles per year
- 150LetPub ·
- Articles per year (publisher) 2025
- 195Publisher website ·
- Downloads per year (publisher) 2025
- 626,659Publisher website ·
Articles by year OpenAlex count · 7,261 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 222 | 143 | 43 |
| 2025 | 226 | 151 | 355 |
| 2024 | 221 | 162 | 1,080 |
| 2023 | 203 | 153 | 1,206 |
| 2022 | 263 | 128 | 2,326 |
| 2021 | 269 | 120 | 2,902 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
135 daysMedian, submission to acceptance · P25–P75 99 days – 192 days
- Acceptance to online
- median 18 days (100 articles)
- Submission to online
- median 163 days
- Sample
- 100 articles with submission and acceptance dates (474 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 3–6 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Acceptance rate (publisher)
- 54%Publisher website ·
- Acceptance rate (publisher) 2025
- 54%Publisher website ·
- Submission to first decision
- 45 daysPublisher website ·
- Submission to first decision 2025
- 45 daysPublisher website ·
- Submission to acceptance 2025
- 126 daysPublisher website ·
- Acceptance to publication 2025
- 18 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,760 / EUR 4,000 / GBP 3,190 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2, with length limits
- original articleing examples of best clinical practice. Original Articles Original articles should not exceed 3,000 words with a maximum of 40 references. Longer Articles will …main text ≤ 3,000 words
- review articleshould be included in the cover letter. Review Articles Review articles should not exceed 4,000 words with a maximum of 60 references. Longer Reviews will be co…main text ≤ 4,000 words
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell Publishing Ltd
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1995
- ISSN
- 1351-8216
- Electronic ISSN
- 1365-2516
- Society / sponsor
- World Federation of Hemophilia and the European Association for Haemophilia
- Latest issue on the website
- Volume 32, Issue 5 (October 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Haemophilia
What CAS zone is Haemophilia in?
In the 2025 upgraded edition of the CAS Journal Ranking, Haemophilia is in Zone 2 of Medicine, and in Zone 2 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Haemophilia?
The latest impact factor listed by LetPub is 2.91; CiteScore 4.4, h-index 123.
How long does peer review take at Haemophilia?
Based on the dates recorded on 100 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 135 days (interquartile range 99–192 days); authors report an average review time of 3–6 weeks; the community-reported acceptance is “Fairly easy”; the journal's website gives an acceptance rate of 54% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Haemophilia based?
Of the 58 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (15), United States (13) and Sweden (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Haemophilia?
According to LetPub and DOAJ records, Haemophilia is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Haemophilia open access, and what is the APC?
Haemophilia is a hybrid journal. For open-access publication: APC about USD 4,760.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .